Davercin - Names and Identifiers
Name | Davercin
|
Synonyms | CWE Davercin DAVERCIN Erythromycin Cyclocarbonate Cykliczny weglan erytromycyny a Carbonato ciclico de eritromicina a Erythromycin A cyclic 11,12-carbonate erythromycin A cyclic 11,12-carbonate Carbonato ciclico de eritromicina A [spanish] (1R,2R,5R,6S,7S,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-6-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-1,5,7,9,11,13-hexamethyl-3,15,17-trioxabicyclo[12.3.0]heptadecane-4,12,16-trione (1R,2R,5R,6S,7S,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-Dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-hydroxy-6-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-1,5,7,9,11,13-hexamethyl-3,15,17-trioxabicyclo[12.3.0]heptadecane-4,12,16-trione (3aR,4R,7R,8S,9S,11R,13R,15R,15aR)-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-ethyl-11-hydroxy-8-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3a,7,9,11,13,15-hexamethyloctahydro-4H-[1,3]dioxolo[4,5-c]oxacyclotetradecine-2,6,14(3aH,7H)-trione (non-preferred name)
|
CAS | 55224-05-0
|
InChI | InChI=1/C38H65NO14/c1-14-25-38(10)32(52-35(44)53-38)20(4)27(40)18(2)16-36(8,45)31(51-34-28(41)24(39(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-37(9,46-13)30(42)23(7)48-26/h18-26,28-32,34,41-42,45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30+,31?,32-,34+,36-,37-,38-/m1/s1 |
Davercin - Physico-chemical Properties
Molecular Formula | C38H65NO14
|
Molar Mass | 759.93 |
Density | 1.22±0.1 g/cm3(Predicted) |
Melting Point | >135°C (dec.) |
Boling Point | 859.8±65.0 °C(Predicted) |
Flash Point | 473.8°C |
Solubility | Chloroform (Slightly), Ethanol (Slightly), Methanol (Slightly) |
Vapor Presure | 1.91E-34mmHg at 25°C |
Appearance | Solid |
Color | White |
pKa | 13.49±0.70(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.534 |
In vitro study | Erythromycin is used in treatment of respiratory, gastrointestinal, and genital tract infections, as well as skin and soft tissue infections. Erythromycin, with its ten chiral centers and two sugar substituents (L-cladinose and D-desosamine), is a good starting point for numerous medicinal chemistry efforts for improvement of its biological profile (better activity, higher stability, and improved bioavailability) since the first generation of macrolides, which had low toxicity and good tolerability, are unstable in acidic media, had low toxicity and good tolerability. |
Davercin - Risk and Safety
Toxicity | LD50 oral in rat: 5800mg/kg |
Davercin - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 1.316 ml | 6.58 ml | 13.159 ml |
5 mM | 0.263 ml | 1.316 ml | 2.632 ml |
10 mM | 0.132 ml | 0.658 ml | 1.316 ml |
5 mM | 0.026 ml | 0.132 ml | 0.263 ml |
Last Update:2024-01-02 23:10:35
Davercin - Introduction
Davercin is a broad-spectrum antibiotic, which belongs to the macrolide family of antibiotics. Its chemical name is 9-{O-[(2-{[4-{[(2-{[2-{[(4-{[(2-{[(1R,2R,3S,4S,6R,8R,10R,11R,12S,13S,15s, 17s)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-] oxy}-1-hydroxyethyl)-] toxy}-5-ethyl-1, 3,4-oxopentan-2-yl] oxy 15-hydroxy-13-methyl-1,5,7,9,14,] oxy}-6-methyll-1-oxobicyclo [11.2.1]hexadec-7-en-17-yl]carbonyl}-11,12-dihy droxy-4-[(2S,4R)-8-methoxy-1-methylethyl]-3,6,10,12,14, 16-hexaoxohexecan-1-yl} nonadecan-21-oate.
Davercin has excellent anti-biological activity and can inhibit the growth of a variety of bacteria. It is mainly used in clinical treatment of a variety of infectious diseases, such as respiratory tract infection, skin and soft tissue infection, ear, nose and throat infection. In addition, Davercin can also be used to treat gastrointestinal infections and sexually transmitted diseases.
The preparation of Davercin is generally obtained by reacting erythromycin with a cyclic ester group. Specific preparation methods include esterification reaction, complexation reaction, etc.
Last Update:2024-04-09 20:52:54